Free Trial

Addex Therapeutics (ADXN) Stock Price, News & Analysis

+0.53 (+6.62%)
(As of 05/28/2024 ET)
Today's Range
50-Day Range
52-Week Range
9,816 shs
Average Volume
16,808 shs
Market Capitalization
$9.05 million
P/E Ratio
Dividend Yield
Price Target
ADXN stock logo

About Addex Therapeutics Stock (NASDAQ:ADXN)

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The CharcotMarieTooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.

ADXN Stock Price History

ADXN Stock News Headlines

Addex Therapeutics Ltd (NASDAQ:ADXN) Short Interest Update
Addex to Present at Bio€quity Europe 2024
Addex Therapeutics Ltd ADR ADXN
Addex to Present at the Swiss Biotech Day 2024
Addex to Present at Biotech Showcase™ 2024
Addex Therapeutics Ltd
Addex Creates Treasury Shares
See More Headlines
Receive ADXN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Addex Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$1.83 million
Book Value
$1.20 per share


Free Float
Market Cap
$9.05 million
Not Optionable
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Timothy Mark Dyer (Age 56)
    Co-Founder, CEO & Director
  • Dr. Roger G. Mills M.D. (Age 67)
    Chief Medical Officer & Director
  • Mr. Lénaic Teyssédou (Age 38)
    Head of Finance
  • Dr. Mikhail Kalinichev Ph.D. (Age 57)
    Head of Translational Science

ADXN Stock Analysis - Frequently Asked Questions

Should I buy or sell Addex Therapeutics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Addex Therapeutics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" ADXN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADXN, but not buy additional shares or sell existing shares.
View ADXN analyst ratings
or view top-rated stocks.

How have ADXN shares performed in 2024?

Addex Therapeutics' stock was trading at $6.05 at the start of the year. Since then, ADXN stock has increased by 41.2% and is now trading at $8.54.
View the best growth stocks for 2024 here

Are investors shorting Addex Therapeutics?

Addex Therapeutics saw a drop in short interest during the month of May. As of May 15th, there was short interest totaling 5,500 shares, a drop of 62.6% from the April 30th total of 14,700 shares. Based on an average trading volume of 19,800 shares, the days-to-cover ratio is presently 0.3 days. Approximately 0.7% of the shares of the company are sold short.
View Addex Therapeutics' Short Interest

When is Addex Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 30th 2024.
View our ADXN earnings forecast

How were Addex Therapeutics' earnings last quarter?

Addex Therapeutics Ltd (NASDAQ:ADXN) released its earnings results on Thursday, April, 18th. The company reported ($4.06) earnings per share for the quarter. The business had revenue of $0.21 million for the quarter. Addex Therapeutics had a negative net margin of 644.66% and a negative trailing twelve-month return on equity of 277.56%.

When did Addex Therapeutics' stock split?

Addex Therapeutics shares reverse split on the morning of Monday, October 23rd 2023. The 1-20 reverse split was announced on Monday, October 23rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Addex Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Addex Therapeutics investors own include Achillion Pharmaceuticals (ACHN), ACADIA Pharmaceuticals (ACAD), Arbutus Biopharma (ABUS), Abacus Property Group (ABP), Advanced BioMedical Technologies (ABMT), Abiomed (ABMD), ARCA biopharma (ABIO), Abeona Therapeutics (ABEO) and Abcam (ABCZY).

How do I buy shares of Addex Therapeutics?

Shares of ADXN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ADXN) was last updated on 5/29/2024 by Staff

From Our Partners